ClinicalTrials.gg
CompletedNCT00054613Updated Aug 16, 2017

Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

A Phase 2 interventional study of Methoxsalen and Extracorporeal Photopheresis in Graft-versus-Host Disease, sponsored by Mallinckrodt. Completed at 31 sites in 12 countries. Per ClinicalTrials.gov, last updated 2017-08-16.

Sponsored by Mallinckrodt · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
62nd of 389
72 · median 30
Started
2002
with 16 others
Phase 2
164 of 454
15 open now
Registered
54th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 62nd largest by enrollment of the 389 interventional ones that give a count, is one of 17 that started in 2002, is one of 164 in phase 2, and was the 54th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether extracorporeal photoimmune therapy with UVADEX (ECP) added to standard therapy is effective in the treatment of chronic graft-versus-host disease (GvHD).

Read the detailed description

For patients who survive allogeneic bone marrow transplants greater than 100 days, chronic GvHD is a major cause of non-relapse morbidity and mortality. Depending on the presence of known associated risk factors, chronic GvHD will occur in 20-50% of these transplant recipients, with mortality rates varying from 20 to 70%.

Because a lymphocyte-mediated immune reaction is thought to be involved in GvHD, suppression of these cells by means other than medications could have benefit in the GvHD population.

ECP is a technique in which peripheral white blood cells are exposed to a photoactivatable compound (UVADEX) administered extracorporeally and ultraviolet A light. After cells are reinfused into the patient, their function is altered, thereby activating mechanisms that allow for further regulation of specific lymphocyte populations.

The purpose of this study is to determine whether ECP, in conjunction with standard therapy, is effective in the treatment of chronic GvHD. Efficacy of the therapy with respect to skin manifestations of the disease will be determined by a blinded skin assessor.

03

Conditions studied

  • Graft-versus-Host Disease

Browse trials for

Keywords

  • Graft-versus-Host Disease
  • Extracorporeal Photopheresis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented skin disease classical for chronic GvHD (e.g. hypopigmentation, hyperpigmentation, lichenoid lesions, sclerodermatous lesions)greater than or equal to 100 days post transplantation.
  • Patients with documented chronic GvHD that is , corticosteroid dependent or corticosteroid intolerant.
  • Women of must agree to use a reliable method of for the duration of this study.
  • Patients must weight at least 40 kg (88 lbs.)

Exclusion criteria

Exclusion Criteria:

  • Active gastrointestinal bleeding
  • Previous treatment with ECP
  • Females who are pregnant and/or lactating
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single
Enrollment
72 participants

Interventions

06

Study locations

31 sites
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Rush Presbyterian - St. Lukes Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Tufts New England Medical Center
    Boston, Massachusetts 02111, United States
  • Brigham and Womens
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-0914, United States
  • Kansas City Cancer Center
    Kansas City, Missouri 64111, United States
  • University of Nebraska
    Omaha, Nebraska 68198-7680, United States
  • Jewish Hospital
    Cincinnati, Ohio 45236, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 19024, United States
  • St. Vincent's Hospital
    Darlinghurst, New South Wales 2010, Australia
  • Peter MacCallum
    East Melbourne, Australia
  • Alfred Hospital
    Melbourne, Australia
  • Royal Melbourne Hospital
    Parkville, 3050, Australia
  • General Hospital of Vienna
    Vienna, A-1090, Austria
  • Hopital Edouard Herriot
    Lyon Cedex 03, 69437, France
  • Hopital Pitie-Salpetriere
    Paris, F-75013, France
  • University of Dresden
    Dresden, D-01307, Germany
  • Universitatis Hautklinik
    Essen, 45122, Germany
  • Universitatsklinikum Leipzig AOR
    Leipzig, D-04103, Germany
  • Ludwig-Maximilians-Universitaet Muenchen
    Munchen, D-81377, Germany
  • Careggi Hospital
    Florence, 1-50134, Italy
  • San Martino Hospital
    Genova, 16132, Italy
  • Instituto Portugues de Oncologia de Francisco Gentil
    Lisboa, 1099-023, Portugal
  • Klinika hematologie a transfuziologie FN
    Bratislava, 81103, Slovakia
  • Hospital dela Santa Creu i Sant Pau. Universitat Autonoma de Barcelona
    Barcelona, E-08025, Spain
  • Kantonsspital Basel
    Basel, CH-4031, Switzerland
  • Ankara University Medical School
    Altındağ, Ankara 6100, Turkey
  • Rotherham General Hospital
    Rotherham, Yorkshire S60 2UD, United Kingdom
  • Glasgow Royal Infirmary
    Glasgow, G4 OS4, United Kingdom
07

References and documents

Publications

  • Smith EP, Sniecinski I, Dagis AC, Parker PM, Snyder DS, Stein AS, Nademanee A, O'Donnell MR, Molina A, Schmidt GM, Stepan DE, Kapoor N, Niland JC, Forman SJ. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transplant. 1998;4(1):27-37. doi: 10.1016/s1083-8791(98)90007-6. PubMed 9701389 ↗
  • Greinix HT, Volc-Platzer B, Knobler RM. Extracorporeal photochemotherapy in the treatment of severe graft-versus-host disease. Leuk Lymphoma. 2000 Feb;36(5-6):425-34. doi: 10.3109/10428190009148389. PubMed 10784386 ↗
  • Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M, Prince HM, Knobler R, Parenti D, Gallo J, Greinix HT. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008 Oct 1;112(7):2667-74. doi: 10.1182/blood-2008-03-141481. Epub 2008 Jul 11. Erratum In: Blood. 2009 Apr 30;113(18):4478. PubMed 18621929 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2003
First posted
Feb 6, 2003
Start
Jun 2002
Completion
Mar 2004
Last update
Aug 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Aug 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00054613
Lead sponsor
Mallinckrodt
First posted
Feb 6, 2003
Start date
Jun 2002
Completion
Mar 2004
Last update
Aug 16, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxsalen

Start the discussion